GRAFALON
LIVE

Serial Number

79414175

Owner

Neovii Biotech GmbH

Attorney

Patrick F. Clunk

Filing Date

Dec 10, 2024

Add to watchlist:

No watchlists yet
View on USPTO

GRAFALON Trademark

Serial Number: 79414175 • Registration: 8163972

GRAFALON is a trademark filed by Neovii Biotech GmbH on December 10, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Neovii Biotech GmbH

Am Haag 6+7

Entity Type: 98

Trademark Details

Filing Date

December 10, 2024

Registration Date

March 10, 2026

Published for Opposition

January 20, 2026

Goods & Services

Medical services; medical, pharmaceutical and biopharmaceutical services in the nature of medical and pharmaceutical consultation and medical advice and information in the field of oncology, hematology, stem cell transplantation, organ transplantation and immunological therapy.

Scientific services and research for medical purposes, namely medical and scientific research in the field of cell biology and antibodies and immunology; scientific and technological services, namely scientific research, analysis, testing in the field of biotechnology, biopharmaceutics and medical science; biotechnological and biopharmaceutical analyses, namely blood analysis services for scientific research purpose, cell analysis services for scientific research purpose, DNA analysis services for scientific research purpose, human leukocyte antigen (HLA) analysis services for scientific research purpose , antibodies analysis services for scientific research purpose, antigen analysis services for scientific research purposes, Technical research in the field of pharmaceutical studies; medical research laboratory services.

Pharmaceutical compositions and preparations, namely, pharmaceutical preparations for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis, aplastic anemia, autoimmune diseases, diabetes, and for the prevention and treatment of graft-versus-host disease, hemophagocytic lymphohistiocytosis, lupus nephritis, multiple sclerosis, myelodysplastic syndrome, myelofibrosis, systemic lupus erythematosus, as well as for use in organ and tissue transplantation; biopharmaceutical compositions and preparations, in particular those for use in the treatment of immunological conditions, tissue, stem cell and organ transplants, tumors and immune system conditions; medicinal preparations for the treatment of infectious diseases and for use in oncology and hematology; medicinal preparations for use in stem cell transplant procedures; medicinal preparations for use in organ transplant procedures.

Filing History

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 10, 2026 FICR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 1, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
May 31, 2026 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 10, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 10, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 20, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jan 20, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 14, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 19, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 18, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 18, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 18, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 18, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 24, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 24, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 24, 2025 TROA
REFUSAL PROCESSED BY IB
Aug 8, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 24, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jul 24, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 1, 2025 RFCR
NON-FINAL ACTION WRITTEN
May 31, 2025 CNRT
ASSIGNED TO EXAMINER
May 28, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 11, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 11, 2025 NWOS
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Jan 2, 2025 SDRC